Physician profile
Geetha Jonnala
NPI 1578690467
$18,399.86
in general payments reported to CMS, 2019-2025
28 companies · $2,921 in 2025
The $2,921 reported for 2025 was more than what 76% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,844 · 2020: $2,433 · 2021: $2,053 · 2022: $3,456 · 2023: $2,644 · 2024: $3,049 · 2025: $2,921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,485 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,484.99 |
| Education | $128.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,147.18 | 2019-2025 | |
| Janssen Biotech, INC. | $2,534.99 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Amgen INC. | $2,204.65 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Novartis Pharmaceuticals Corporation | $1,284.73 | 2019-2025 | |
| Pfizer INC. | $1,107.89 | 2019-2025 | |
| Genzyme Corporation | $886.54 | 2019-2025 | |
| Glaxosmithkline, LLC. | $809.59 | 2019-2025 | Benlysta, Nucala |
| Mallinckrodt Hospital Products INC. | $590.90 | 2021-2025 | Acthar |
| Ucb, INC. | $582.61 | 2020-2025 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $544.48 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $376.80 | 2021-2025 | Saphnelo |
| Sobi, INC | $226.04 | 2019-2025 | |
| Radius Health, INC. | $217.41 | 2023-2025 | Tymlos |
| Horizon Therapeutics Plc | $212.82 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $154.71 | 2019-2025 | Actemra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $112.20 | 2023-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $70.59 | 2021-2024 | Taltz |
| Invivyd INC | $58.22 | 2025 | Pemgarda |
| Tonix Medicines, INC. | $41.89 | 2025 | Tonmya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.26 | 2021-2022 | |
| Celgene Corporation | $37.51 | 2019 | |
| Arcutis Biotherapeutics, INC. | $33.51 | 2023 | |
| Medexus Pharma, INC. | $31.57 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $25.38 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $21.14 | 2019 | |
| Organon LLC | $17.49 | 2025 | Hadlima, Renflexis |
| Alexion Pharmaceuticals, INC. | $15.74 | 2025 | Strensiq |
| Fresenius Kabi USA, LLC | $15.02 | 2025 | Tyenne |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geetha Jonnala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.